AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer

Overview

Journal Cancer Res

Specialty Oncology

Date 2024 Jan 8

PMID 38190717

Authors

Mauricio Marquez-Palencia

Luis Reza Herrera

Pravat Kumar Parida

Suvranil Ghosh

Kangsan Kim

Nikitha M Das

Paula I Gonzalez-Ericsson

Melinda E Sanders

Bret C Mobley

Sebastian Diegeler

Todd A Aguilera

Yan Peng

Cheryl M Lewis

Carlos L Arteaga

Ariella B Hanker

Angelique W Whitehurst

James B Lorens

Rolf A Brekken

Anthony J Davis

Srinivas Malladi

Affiliations

Soon will be listed here.

Abstract

Significance: Nuclear AXL and WRNIP1 interact and mediate replication stress response, promote therapy resistance, and support metastatic progression, indicating that targeting the AXL/WRNIP1 axis is a potentially viable therapeutic strategy for breast cancer.

Citing Articles

Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?.

Malikova I, Worth A, Aliyeva D, Khassenova M, Kriajevska M, Tulchinsky E Cell Death Dis. 2025; 16(1):155.

PMID: 40044635 PMC: 11883011. DOI: 10.1038/s41419-025-07480-9.

AXL signaling in cancer: from molecular insights to targeted therapies.

Yadav M, Sharma A, Patne K, Tabasum S, Suryavanshi J, Rawat L Signal Transduct Target Ther. 2025; 10(1):37.

PMID: 39924521 PMC: 11808115. DOI: 10.1038/s41392-024-02121-7.

AXL: shapers of tumor progression and immunosuppressive microenvironments.

Liu Y, Xu L, Dou Y, He Y Mol Cancer. 2025; 24(1):11.

PMID: 39799359 PMC: 11724481. DOI: 10.1186/s12943-024-02210-9.

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review.

Zhong H, Zhou Z, Wang H, Wang R, Shen K, Huang R Int J Mol Sci. 2025; 25(24.

PMID: 39769140 PMC: 11677710. DOI: 10.3390/ijms252413376.

Dendritic polylysine co-delivery of paclitaxel and siAXL enhances the sensitivity of triple-negative breast cancer chemotherapy.

Wan X, Chen C, Zhan J, Ye S, Li R, Shen M Front Bioeng Biotechnol. 2024; 12:1415191.

PMID: 39148942 PMC: 11324506. DOI: 10.3389/fbioe.2024.1415191.

References

Murthy R, Borges V, Conlin A, Chaves J, Chamberlain M, Gray T . Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018; 19(7):880-888. DOI: 10.1016/S1470-2045(18)30256-0. View

Revach O, Sandler O, Samuels Y, Geiger B . Cross-Talk between Receptor Tyrosine Kinases AXL and ERBB3 Regulates Invadopodia Formation in Melanoma Cells. Cancer Res. 2019; 79(10):2634-2648. DOI: 10.1158/0008-5472.CAN-18-2316. View

Terry S, Abdou A, Engelsen A, Buart S, Dessen P, Corgnac S . AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity. Cancer Immunol Res. 2019; 7(11):1789-1802. DOI: 10.1158/2326-6066.CIR-18-0903. View

Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona M . Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. Crit Rev Oncol Hematol. 2019; 139:53-66. DOI: 10.1016/j.critrevonc.2019.05.001. View

Malladi S, Macalinao D, Jin X, He L, Basnet H, Zou Y . Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell. 2016; 165(1):45-60. PMC: 4808520. DOI: 10.1016/j.cell.2016.02.025. View

Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S . Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2021; 33(3):321-329. DOI: 10.1016/j.annonc.2021.12.005. View

Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S . The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014; 507(7493):508-12. PMC: 6258903. DOI: 10.1038/nature12998. View

Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R . Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009; 69(17):6871-8. DOI: 10.1158/0008-5472.CAN-08-4490. View

Li B, Smit E, Goto Y, Nakagawa K, Udagawa H, Mazieres J . Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2021; 386(3):241-251. PMC: 9066448. DOI: 10.1056/NEJMoa2112431. View

10.

Lin N, Borges V, Anders C, Murthy R, Paplomata E, Hamilton E . Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020; 38(23):2610-2619. PMC: 7403000. DOI: 10.1200/JCO.20.00775. View

11.

Sutcliffe M, Galvao R, Wang L, Kim J, Rosenfeld L, Singh S . Premalignant Oligodendrocyte Precursor Cells Stall in a Heterogeneous State of Replication Stress Prior to Gliomagenesis. Cancer Res. 2021; 81(7):1868-1882. PMC: 8137536. DOI: 10.1158/0008-5472.CAN-20-1037. View

12.

Pantel K, Hayes D . Disseminated breast tumour cells: biological and clinical meaning. Nat Rev Clin Oncol. 2017; 15(3):129-131. DOI: 10.1038/nrclinonc.2017.174. View

13.

Hong C, Lay J, Huang J, Cheng A, Tang J, Lin M . Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett. 2008; 268(2):314-24. DOI: 10.1016/j.canlet.2008.04.017. View

14.

Kim K, Marquez-Palencia M, Malladi S . Metastatic Latency, a Veiled Threat. Front Immunol. 2019; 10:1836. PMC: 6691038. DOI: 10.3389/fimmu.2019.01836. View

15.

Lambert A, Pattabiraman D, Weinberg R . Emerging Biological Principles of Metastasis. Cell. 2017; 168(4):670-691. PMC: 5308465. DOI: 10.1016/j.cell.2016.11.037. View

16.

Brastianos P, Carter S, Santagata S, Cahill D, Taylor-Weiner A, Jones R . Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015; 5(11):1164-1177. PMC: 4916970. DOI: 10.1158/2159-8290.CD-15-0369. View

17.

Alexander P, Chen R, Gong C, Yuan L, Jasper J, Ding Y . Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer. J Biol Chem. 2016; 292(2):748-759. PMC: 5241747. DOI: 10.1074/jbc.M116.754960. View

18.

Schlam I, Tarantino P, Tolaney S . Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. Cancers (Basel). 2022; 14(16). PMC: 9406173. DOI: 10.3390/cancers14163996. View

19.

Axelrod H, Valkenburg K, Amend S, Hicks J, Parsana P, Torga G . AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Mol Cancer Res. 2018; 17(2):356-369. PMC: 6359976. DOI: 10.1158/1541-7786.MCR-18-0718. View

20.

Lin J, Wang Z, De W, Zheng M, Xu W, Wu H . Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer. Oncotarget. 2017; 8(25):41064-41077. PMC: 5522277. DOI: 10.18632/oncotarget.17026. View